David E. Gerber
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
-
- Lung Cancer Diagnosis and Treatment 71
- Lung Cancer Treatments and Mutations 69
- Oncology 88
- Cancer Immunotherapy and Biomarkers 63
- Lung Cancer Research Studies 9
- Co-authors
- Lorraine Cheryl Pelosof (2 shared papers)Yang Xie (33 shared papers)John Dorrance Minna (14 shared papers)Sandi L. Pruitt (18 shared papers)Shaheen Khan (7 shared papers)Jonathan E. Dowell (22 shared papers)Joan H. Schiller (16 shared papers)Julie Renee Brahmer (14 shared papers)
- Journals
- Journal of Thoracic Oncology (27 papers)Lung Cancer (18 papers)Clinical Lung Cancer (16 papers)International Journal of Radiation Oncology*Biology*Physics (12 papers)JAMA Oncology (11 papers)
- Partner nations
- United StatesCanadaChina
In The Last Decade
David E. Gerber
273 papers receiving 20.2k citations
David E. Gerber's Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 10.5k
- Pulmonary and Respiratory Medicine 6.1k
- Internal Medicine 196
- Cancer Research 793
- Toxicology 231
Countries citing papers authored by David E. Gerber
This map shows the geographic impact of David E. Gerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Gerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Gerber more than expected).
Fields of papers citing papers by David E. Gerber
This network shows the impact of papers produced by David E. Gerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Gerber. The network helps show where David E. Gerber may publish in the future.
Co-authors
The 25 scholars most cited alongside David E. Gerber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 287 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 8030 |
| 2 | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study Hit paper breakdown → | 2016 | 823 |
| 3 | Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 816 |
| 4 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events Hit paper breakdown → | 2021 | 668 |
| 5 | 2010 | 497 | |
| 6 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 483 |
| 7 | 2016 | 441 | |
| 8 | 2016 | 386 | |
| 9 | Targeted therapies: a new generation of cancer treatments. | 2008 | 345 |
| 10 | 2011 | 337 | |
| 11 | 2014 | 247 | |
| 12 | 2010 | 182 | |
| 13 | 2019 | 178 | |
| 14 | 2018 | 164 | |
| 15 | 2018 | 161 | |
| 16 | 2016 | 153 | |
| 17 | 2018 | 147 | |
| 18 | 2022 | 140 | |
| 19 | 2013 | 139 | |
| 20 | 2016 | 130 |
About David E. Gerber
David E. Gerber is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Public Health, Environmental and Occupational Health, Health Information Management and Statistics and Probability, having authored 287 papers that have together received 20.6k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (71 papers), Lung Cancer Treatments and Mutations (69 papers), Cancer Immunotherapy and Biomarkers (63 papers), Ethics in Clinical Research (23 papers), Multiple and Secondary Primary Cancers (11 papers), Lung Cancer Research Studies (9 papers), Statistical Methods in Clinical Trials (8 papers) and Health and Medical Research Impacts (7 papers). The work is most often cited by research in Oncology (10.5k citations), Pulmonary and Respiratory Medicine (6.1k citations), Internal Medicine (196 citations), Cancer Research (793 citations) and Toxicology (231 citations). David E. Gerber has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Lorraine Cheryl Pelosof, Yang Xie, John Dorrance Minna, Sandi L. Pruitt, Shaheen Khan, Jonathan E. Dowell, Joan H. Schiller, Julie Renee Brahmer, Frances A. Shepherd and Rosalyn Anne Juergens. Their work appears in journals such as Journal of Thoracic Oncology, Lung Cancer, Clinical Lung Cancer, International Journal of Radiation Oncology*Biology*Physics and JAMA Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.